Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.38
+5.8%
$1.56
$0.87
$3.08
$99.41M-0.311.36 million shs1.26 million shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.78
+6.9%
$2.91
$2.43
$13.95
$22.17M0.52631,183 shs94,647 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.30
+11.7%
$5.28
$3.90
$15.00
$117.96M0.69269,675 shs2.06 million shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$6.20
+5.5%
$6.11
$3.28
$9.82
$106.43M1.49115,871 shs34,357 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-5.11%-4.41%-5.11%-5.11%-47.79%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-5.11%-17.20%-3.35%-6.14%-68.78%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-3.48%+3.35%+53.22%+77.02%-35.25%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+1.38%-3.14%-6.38%+12.88%+10.53%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.38
+5.8%
$1.56
$0.87
$3.08
$99.41M-0.311.36 million shs1.26 million shs
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
$2.78
+6.9%
$2.91
$2.43
$13.95
$22.17M0.52631,183 shs94,647 shs
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.30
+11.7%
$5.28
$3.90
$15.00
$117.96M0.69269,675 shs2.06 million shs
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$6.20
+5.5%
$6.11
$3.28
$9.82
$106.43M1.49115,871 shs34,357 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-5.11%-4.41%-5.11%-5.11%-47.79%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-5.11%-17.20%-3.35%-6.14%-68.78%
Lifevantage Corporation stock logo
LFVN
Lifevantage
-3.48%+3.35%+53.22%+77.02%-35.25%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
+1.38%-3.14%-6.38%+12.88%+10.53%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
2.75
Moderate Buy$8.50518.18% Upside
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.50
Moderate Buy$11.00295.83% Upside
Lifevantage Corporation stock logo
LFVN
Lifevantage
2.00
Hold$5.00-46.21% Downside
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
2.25
Hold$14.50134.06% Upside

Current Analyst Ratings Breakdown

Latest CLRB, BMEA, LFVN, and VRCA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
UpgradeHold (C-)Hold (C)
5/26/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
Initiated CoverageBuy$12.00
5/15/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Initiated CoverageBuy
5/11/2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
UpgradeStrong SellHold
5/7/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeBuyHold$5.00
5/5/2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
Reiterated RatingBuy$11.00
5/5/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Initiated CoverageBuyOutperform
5/5/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Initiated CoverageMarket Outperform$9.00
5/4/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
DowngradeHold (C)Hold (C-)
4/28/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated RatingBuy$12.00
4/20/2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Reiterated RatingSell (E+)
(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$0.42 per shareN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/A$1.89 per shareN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$195.32M0.60$1.19 per share7.84$2.75 per share3.38
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
$35.58M2.99N/AN/A$1.55 per share4.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$21.79M-$6.66N/AN/AN/AN/A-349.24%-153.18%8/13/2026 (Estimated)
Lifevantage Corporation stock logo
LFVN
Lifevantage
$9.81M$0.4520.7814.30N/A2.94%23.89%12.47%N/A
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$17.89M-$1.03N/AN/AN/A-47.97%-1,077.78%-40.76%8/11/2026 (Estimated)

Latest CLRB, BMEA, LFVN, and VRCA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$1.8850-$1.33+$0.5550-$1.33$8.00 millionN/A
5/12/2026Q1 2026
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.59-$0.41+$0.18-$0.45$4.51 million$5.02 million
5/11/2026Q1 2026
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.24-$0.17+$0.07-$0.17N/AN/A
5/6/2026Q3 2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.12-$0.04$0.11$47.77 million$43.72 million
3/11/2026Q4 2025
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
-$0.43-$0.51-$0.08-$0.57$4.52 million$5.09 million
3/4/2026Q4 2025
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
-$1.19-$0.53+$0.66-$0.53N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/AN/AN/AN/AN/A
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.202.15%N/A44.44%3 Years
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
N/AN/AN/AN/AN/A

Latest CLRB, BMEA, LFVN, and VRCA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/27/2026
Lifevantage Corporation stock logo
LFVN
Lifevantage
quarterly$0.052.12%6/1/20266/1/20266/15/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
4.98
4.98
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
N/A
1.90
1.90
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.96
1.04
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
0.03
2.10
1.98

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
16.41%
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
42.45%

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
10.60%
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
2.58%
Lifevantage Corporation stock logo
LFVN
Lifevantage
21.95%
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
54.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5072.30 million64.64 millionOptionable
Cellectar Biosciences, Inc. stock logo
CLRB
Cellectar Biosciences
107.99 million7.79 millionNo Data
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.62 million9.85 millionOptionable
Verrica Pharmaceuticals Inc. stock logo
VRCA
Verrica Pharmaceuticals
4017.18 million7.90 millionNo Data

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.38 +0.08 (+5.77%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Cellectar Biosciences stock logo

Cellectar Biosciences NASDAQ:CLRB

$2.78 +0.18 (+6.88%)
As of 03:01 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$9.30 +0.98 (+11.72%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

Verrica Pharmaceuticals stock logo

Verrica Pharmaceuticals NASDAQ:VRCA

$6.20 +0.33 (+5.54%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.